Max Healthcare
Market cap ₹81,271 Cr
- P/E
- 56.00
- Day range
- ₹812.05 – ₹843.00
- 52-week range
- ₹797.00 – ₹1,194.40
- Volume
- 24.75 L
- Open
- ₹819.05
- Prev close
- ₹815.00
Latest results · Q1 FY27(consolidated)Revenue ₹2,366 Cr+16.7%Profit ₹323 Cr+4.9%Margin 13.6%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
MAXHEALTH in NSE indices and F&O
F&O margin for one lot of MAXHEALTH (525 shares)Research profile
Composite 44 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.8%
- Graham no.
- ₹197.47
- vs Graham
- -76.4%
- ROE ÷ P/B
- 1.9%
- 12-1 mom.
- -9.0%
- Return / vol
- -1.12
- Magic Formula
- #490
- Piotroski
- 3/6
- FCF yield
- 0.2%
- PEG
- 7.51
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.17 L Cr | 34.52 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.40 L Cr | 82.12 | 14.18 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.73 L Cr | 76.86 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.16 L Cr | 25.86 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.13 L Cr | 53.97 | 11.73 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Laurus LabsLAURUSLABS | ₹1.11 L Cr | 101.77 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| CiplaCIPLA | ₹1.09 L Cr | 32.49 | 3.14 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Max HealthcareMAXHEALTH | ₹81,271 Cr | 56.00 | 7.41 | 14.3% | 15.0% | 25.0% | 0.32 | +16.7% |
| Sector median | ₹24,447 Cr | 41.53 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 8d agoHeadlines about Max Healthcare from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 54.2
- EPS (TTM)
- ₹14.98
- Price / Book
- 7.59
- ROE (FY26)
- 14.3%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.24%
Moving averages (NSE)
- 20-day
- ₹898.15
- Price below
- 50-day
- ₹969.64
- Price below
- 200-day
- ₹1,019.14
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- FII
- DII
- Promoter
- Public
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,363 | 1,335 | 1,423 | 1,543 | 1,707 | 1,868 | 1,910 | 2,028 | 2,135 | 2,068 | 2,143 | 2,366 |
| Expenses | 976 | 949 | 1,041 | 1,156 | 1,257 | 1,369 | 1,398 | 1,505 | 1,560 | 1,529 | 1,536 | 1,768 |
| Operating Profit | 387 | 386 | 382 | 387 | 451 | 499 | 512 | 523 | 575 | 538 | 606 | 598 |
| OPM % | 28% | 29% | 27% | 25% | 26% | 27% | 27% | 26% | 27% | 26% | 28% | 25% |
| Other Income | 45 | 46 | 45 | 35 | 41 | -40 | 47 | 37 | 33 | -3 | 48 | 41 |
| Interest | 9 | 11 | 21 | 24 | 34 | 52 | 55 | 55 | 54 | 60 | 67 | 71 |
| Depreciation | 58 | 61 | 70 | 77 | 84 | 98 | 101 | 104 | 108 | 111 | 123 | 132 |
| Profit before tax | 366 | 360 | 336 | 321 | 374 | 309 | 402 | 400 | 446 | 365 | 465 | 436 |
| Tax % | 24% | 20% | 25% | 26% | 25% | 23% | 21% | 23% | -10% | 17% | 26% | 26% |
| Net Profit | 277 | 289 | 252 | 236 | 282 | 239 | 319 | 308 | 491 | 301 | 342 | 323 |
| EPS in Rs | ₹2.85 | ₹2.98 | ₹2.59 | ₹2.43 | ₹2.90 | ₹2.46 | ₹3.28 | ₹3.17 | ₹5.05 | ₹3.09 | ₹3.52 | ₹3.32 |
From company filings, updated 27 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-11 days since Mar 2021
-11 days since Mar 2021
-99 days since Mar 2021
+77 days since Mar 2021
+3 days since Mar 2021
Strengths, risks & growth
Max Healthcare Institute Limited is primarily engaged in the providing healthcare services through primary care clinics, multi-speciality hospitals / medical centres and super-speciality hospitals providing operation and management, medical services, clinical, radiology, pathology services and related healthcare services. [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 7.56 times its book value
- Tax rate seems low
- Company has a low return on equity of 13.7% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 13.6% of profits over last 3 years
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +27%
- 3 Years
- +22%
- TTM
- +16%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +60%
- 3 Years
- +10%
- TTM
- +25%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- +20%
- 3 Years
- +14%
- 1 Year
- -29%
Return on Equity
- 10 Years
- +11%
- 5 Years
- +14%
- 3 Years
- +14%
- Last Year
- +15%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 23.72% | 23.71% | 23.71% | 23.71% | 0.00 pp |
| FII | 50.55% | 45.39% | 41.78% | 40.52% | -1.26 pp |
| DII | 21.20% | 26.32% | 29.95% | 31.01% | +1.06 pp |
| Public | 4.52% | 4.58% | 4.55% | 4.76% | +0.21 pp |
Filed with NSE for Sept 2026: promoters 23.71%, public 76.29% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 19.25% (+0.57 pp)- Promoters23.7%
- Foreign institutions40.5%
- Mutual funds19.3%
- Insurance8.1%
- Other domestic institutions3.7%
- Retail2.3%
- Others2.5%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Flexi Cap Fund | 1.93% | 1.46% | -0.10 pp |
| Invesco India Midcap Fund | 1.38% | 7.21% | +2.91 pp |
| Invesco India Large & Mid Cap Fund | 0.99% | 6.67% | -1.08 pp |
| Nippon India Growth Mid Cap Fund | 0.89% | 1.46% | -0.10 pp |
| Kotak Mid Cap Fund | 0.82% | 1.01% | +0.12 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 26.5%
- Downside volatility
- 27.6%
- Worst 5% of days
- 2.9%
- Average of that tail
- 3.8%
- Max drawdown (1Y)
- 32.7%
- Below its peak
- 32.7%
Against the market
- Beta vs Nifty 50
- 0.68
- Correlation
- 0.34
- Relative strength (3M)
- -19.5%
- ATR (14)
- 3.4%
Return
- Return 1M
- -22.9%
- Return 3M
- -24.8%
- Return 6M
- -18.9%
- Return 1Y
- -29.8%
- vs 200-day average
- -20.0%
Momentum
- RSI (14) · oversold
- 20.8
- MACD histogram
- -5.71
- Stochastic %K
- 12.6
- ADX (14)
- 45.8
- +DI / −DI
- 8.4 / 36.6
- Money flow index
- 33.9
Participation
- Delivery (20d avg)
- 55.3%
- vs its 60-day baseline
- -0.6 pts
- Volume vs 20-day
- +0.1σ
- Close vs day's VWAP
- +0.0%
- 52-week position
- 0 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹149 Cr
- FCF yield
- 0.2%
- Cash conversion
- 1.13
- Accruals ratio
- -0.011
- Net debt
- ₹2,813 Cr
- Net debt / equity
- 0.26
- EV / sales
- 9.43
- PEG
- 7.51
- Capex intensity
- 17.7%
- Revenue CAGR
- 12.2%
- Profit CAGR
- 7.3%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹2.00
Dividend - Rs 2 Per Share
3 Jul 2026ex-date - dividend₹1.50
Dividend - Rs 1.50 Per Share
4 Jul 2025ex-date - dividend₹1.50
Dividend - Rs 1.5 Per Share
23 Aug 2024ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
8 Sept 2023ex-date
Company announcements
Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Voting Results and Scrutinizer's Report on Postal Ballot
Voting Results and Scrutinizer's Report on Postal Ballot
Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Rating by CARE Ratings Limited
Rating by CARE Ratings Limited
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Newspaper Publication - Postal Ballot Notice
Postal Ballot Notice
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Schedule of Investor Conference
Schedule of Investor Conference
Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Filed with BSE (scrip 543220); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Aug 2026TranscriptSlidesRecording
- Aug 2026Slides
- May 2026TranscriptSlidesRecording
- May 2026Slides
- Feb 2026TranscriptSlides
- Feb 2026SlidesRecording
Credit ratings
- Rating update · 12 Oct from care
- Rating update · 10 Oct 2025 from care
- Rating update · 4 Apr 2025 from care
- Rating update · 3 Oct 2024 from care
- Rating update · 9 Oct 2023 from care
- Rating update · 22 Nov 2022 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 13 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Max Healthcare: common questions
Answered from the figures on this page.
